Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome
LB Gordon, H Shappell, J Massaro, RB D'Agostino… - Jama, 2018 - jamanetwork.com
Importance Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal
premature aging disease. There is no approved treatment. Objective To evaluate the …
premature aging disease. There is no approved treatment. Objective To evaluate the …
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome
LB Gordon, J Massaro, RB D'Agostino Sr… - Circulation, 2014 - Am Heart Assoc
Background—Hutchinson-Gilford progeria syndrome is an ultrarare segmental premature
aging disease resulting in early death from heart attack or stroke. There is no approved …
aging disease resulting in early death from heart attack or stroke. There is no approved …
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
LB Gordon, ME Kleinman, DT Miller… - Proceedings of the …, 2012 - National Acad Sciences
Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …
Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford progeria syndrome
LB Gordon, ME Kleinman, J Massaro… - Circulation, 2016 - Am Heart Assoc
Background: Hutchinson-Gilford progeria syndrome is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA yielding the farnesylated …
premature aging syndrome caused by a mutation in LMNA yielding the farnesylated …
[HTML][HTML] Hutchinson-Gilford progeria syndrome
LB Gordon, WT Brown, FS Collins - 2019 - europepmc.org
Hutchinson-Gilford progeria syndrome (HGPS) is characterized by clinical features that
typically develop in childhood and resemble some features of accelerated aging. Children …
typically develop in childhood and resemble some features of accelerated aging. Children …
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development
LB Gordon, KM McCarten, A Giobbie-Hurder… - …, 2007 - publications.aap.org
OBJECTIVES. Hutchinson-Gilford progeria syndrome is a rare and uniformly fatal segmental
“premature aging” disease that affects a variety of organ systems. We sought to more clearly …
“premature aging” disease that affects a variety of organ systems. We sought to more clearly …
Phenotype and course of Hutchinson–Gilford progeria syndrome
MA Merideth, LB Gordon, S Clauss… - New England journal …, 2008 - Mass Medical Soc
Background Hutchinson–Gilford progeria syndrome is a rare, sporadic, autosomal dominant
syndrome that involves premature aging, generally leading to death at approximately 13 …
syndrome that involves premature aging, generally leading to death at approximately 13 …
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson–Gilford progeria syndrome
Hutchinson–Gilford progeria syndrome (HGPS) is a rare, invariably fatal childhood
premature aging disorder caused by a pre-messenger RNA (mRNA) splicing defect in the …
premature aging disorder caused by a pre-messenger RNA (mRNA) splicing defect in the …
Hutchinson–Gilford progeria syndrome
NJ Ullrich, LB Gordon - Handbook of clinical neurology, 2015 - Elsevier
Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, uniformly fatal,
segmental “premature aging” disease in which children exhibit phenotypes that may give us …
segmental “premature aging” disease in which children exhibit phenotypes that may give us …
関連 キーワード
- hutchinson gilford progeria syndrome
- lonafarnib treatment progeria syndrome
- hutchinson gilford lonafarnib treatment
- lonafarnib treatment mortality rate
- mortality rate progeria syndrome
- hutchinson gilford mortality rate
- hutchinson gilford farnesylation inhibitors
- disease progression progeria syndrome
- farnesylation inhibitors progeria syndrome
- hutchinson gilford disease progression
- impact on growth progeria syndrome
- hutchinson gilford impact on growth
- cardiac abnormalities progeria syndrome
- hutchinson gilford cardiac abnormalities
- zoledronic acid progeria syndrome
- hutchinson gilford zoledronic acid